Medtronic has delivered four consecutive earnings beats on a foundation of near-perfect financial health metrics, but the stock is in a confirmed technical downtrend, options positioning signals unusual caution at a put/call ratio of roughly 5.7, and sole-source supplier dependencies represent a supply-chain vulnerability that limits conviction to add at current prices.
Thesis pillars
- Consistent Earnings Delivery↑Improving
- Strong Financial Health Score→Stable
- Confirmed Technical Downtrend↑Improving
- +2 more pillars — see the Why tab for full reasoning
Medtronic plc. (MDT) Stock Analysis
Breakout setup
Healthcare · Medical Devices
Hold if already holding. Not a fresh buy at $94.23, but acceptable to hold if already in. Reasons: Concentration risk — Supplier: sole suppliers for components, raw materials and services; Analyst target reached - limited upside remaining.
Medtronic plc, headquartered in Galway, Ireland, develops, makes and sells device-based medical therapies in more than 150 countries through four segments: Cardiovascular, Neuroscience, Medical Surgical and the Diabetes Operating Unit. It has over 95,000 full-time employees, and... Read more
Hold if already holding. Not a fresh buy at $94.23, but acceptable to hold if already in. Reasons: Concentration risk — Supplier: sole suppliers for components, raw materials and services; Analyst target reached - limited upside remaining. Chart setup: Golden cross, above all MAs, RSI 68, MACD bullish. Maintain position. Not compelling to add more. Score 6.4/10, moderate confidence.
Passes 6/7 gates (positive momentum, clean insider activity, no SEC red flags, earnings proximity 34d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: moderate.
About Medtronic plc.
About Medtronic plc.
Medtronic plc serves healthcare systems, physicians and patients in more than 150 countries through four reportable segments: the Cardiovascular Portfolio, the Neuroscience Portfolio, the Medical Surgical Portfolio and the Diabetes Operating Unit. The company, headquartered in Galway, Ireland, has over 95,000 full-time employees, 44% of them based in the U.S. or Puerto Rico. In May 2025 it announced its intention to separate the Diabetes business into an independent publicly traded company within 18 months.
Cardiovascular sells pacemakers such as the Micra leadless system, defibrillators, ablation products including Arctic Front, PulseSelect and Sphere-9, Evolut transcatheter aortic valves, coronary stents and the Symplicity renal denervation system. Neuroscience covers spine implants, Mazor robotic guidance, Infuse bone graft, spinal cord stimulation such as Inceptiv, and Percept brain stimulation. Medical Surgical offers stapling and energy products, the Hugo robotic-assisted surgery system, and Nellcor pulse oximetry monitoring. Diabetes sells the MiniMed 780G insulin pump, Simplera continuous glucose monitoring and the InPen smart pen. Hospitals and physicians typically buy these devices and bill Medicare, Medicaid and private plans, so reimbursement decisions affect which products customers choose. The company manufactures the majority of its products at facilities worldwide, and competitors range from large multi-line companies to small niche makers, plus drug makers producing GLP-1 therapies.
Show full overview
Regulatory and quality exposure frames the main risk. FDA inspections of the company's and its suppliers' facilities have produced Form 483 observations and warning letters in the past, and the agency could order recalls or pursue a consent decree if it found noncompliance. EU Medical Device Regulation deadlines were extended to the end of 2027 for high-risk devices and the end of 2028 for medium- and low-risk devices. Certain components, raw materials and services come from sole suppliers, and several key products rely on a particular sterilization facility with constrained capacity. Medtronic stopped selling the HVAD System in June 2021.
See also: Healthcare · Medical Devices
From Medtronic plc.'s most recent 10-K filing, extracted October 11, 2026.
Recent developments
updated 2026-10-15Recent Developments — Medtronic plc.
Latest news
- NEWS Is Medtronic’s (MDT) Pain-Portfolio Pivot Offsetting Quality Scrutiny From Its Pediatric Cannula Recall? - simplywall.st — simplywall.st negative
- NEWS MDT Adds Rem700 Short Action Left Hand to CRBN Rifle Stock Lineup - Outdoor Wire — Outdoor Wire neutral
- NEWS Medtronic PLC $MDT Stock Position Decreased by California State Teachers Retirement System - MarketBeat — MarketBeat negative
- NEWS Is Medtronic’s (MDT) Pain-Portfolio Pivot Offsetting Quality Scrutiny From Its Pediatric Cannula Recall? - Sahm — Sahm negative
- NEWS Is Medtronic’s (MDT) Pain-Portfolio Pivot Offsetting Quality Scrutiny From Its Pediatric Cannula Recall? - sahmcapital.c — sahmcapital.com negative
Generated 2026-10-15T11:32:14Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHSuppliersole suppliers for components, raw materials and services10-K Item 1A: 'certain components, raw materials and services needed to manufacture our products are obtained from sole suppliers'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $94.23, but acceptable to hold if already in. Reasons: Concentration risk — Supplier: sole suppliers for components, raw materials and services; Analyst target reached - limited upside remaining. Chart setup: Golden cross, above all MAs, RSI 68, MACD bullish. Maintain position. Not compelling to add more. Target $108.36 (+15.0%), stop $89.27 (−5.6%), A.R:R -0.0:1. Score 6.4/10, moderate confidence.
Take-profit target: $108.36 (-0.3% upside). Target $108.36 (+15.0%), stop $89.27 (−5.6%), A.R:R -0.0:1. Stop-loss: $89.27.
Concentration risk — Supplier: sole suppliers for components, raw materials and services; Analyst target reached - limited upside remaining; Negative news sentiment (-0.53).
Medtronic plc. trades at a P/E of 22.9 (forward 14.5). TrendMatrix value score: 5.8/10. Verdict: Hold.
34 analysts cover MDT with a consensus score of 4.0/5. Average price target: $104.
What does Medtronic plc. do?Medtronic plc, headquartered in Galway, Ireland, develops, makes and sells device-based medical therapies in more than...
Medtronic plc, headquartered in Galway, Ireland, develops, makes and sells device-based medical therapies in more than 150 countries through four segments: Cardiovascular, Neuroscience, Medical Surgical and the Diabetes Operating Unit. It has over 95,000 full-time employees, and customers are mainly hospitals and physicians that bill Medicare, Medicaid and private insurers. In May 2025 it announced plans to separate the Diabetes business into an independent public company.